Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.62) by 33.87 percent.
Read How Analysts Reacted To Cintas’ Q4 Results
RBC Capital analyst Ashish Sabadra lowered the price target on Cintas Corp (NASDAQ:CTAS) to $450 (an upside of 16%) from $475, citing elevated…